2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous

Size: px
Start display at page:

Download "2. Date of most recent breast cancer diagnosis / / 3. Pathlogy: Padget s Phyllodes Tubular Medullary Mucinous"

Transcription

1 Breast Cancer Patients: Begin on page 1, then skip to page 3 Lymphoma Patients: Begin on page 2 1. Newly diagnosed with Breast carcinoma Stage: (includes inflammatory breast and newly diagnosed recurrent breast) Date of most recent breast cancer diagnosis / / 3. Pathlogy: DCIS Ductal Carcinoma In Situ ILC Invasive Lobular Carcinoma IDC Invasive Ductal Carcinoma LCIS - Lobular Carcinoma In Situ Padget s Phyllodes Tubular Medullary Mucinous Papillary Cribiform Other: Specify 4. Complete the following staging criteria: T N M 5. Indicate hormonal status: ER negative positive % if known PR negative positive % if known HER2 negative positive Unknown If positive: Has been diagnosed (lab confirmed) with any of the following hereditary genes? BRCA1 BRCA2 Tp53 7. Current menstrual status: Pre -menopausal 8. Had prior surgical removal of: (Check all that apply) Peri / Post-menopausal (Post-menopausal defined as no amenorrhea x 1 year or oophorectomy) Uterus Right ovary Left ovary Partial removal of ovary 9. Chemotherapy will be adjuvant or neoadjuvant 10. Past hormonal therapy? (If Yes, check all that apply) Tamoxifen (Nolvadex) Arimidex Femara Raloxifene (Evista) Aromasin Zoladex injection Faslodex injection Other hormonal therapy (Specify) 11. Does patient have tissue expanders? If yes, will they be removed prior to the 6 month cardiac MRI? (Baseline MRI will not be obtained.) 12. Does patient have breast implants? (Most implants are permitted during an MRI. Check with MRI technician to confirm)

2 Complete this page for Lymphoma patients 1. Newly diagnosed with lymphoma Stage: Date of lymphoma diagnosis / / 3. Pathlogy: Hodgkin's Classic Hodgkin's lymphoma Nodular Lymphocyte Predominant Hogkin s lymphoma Or non-hodgkin's Diffuse Large B-Cell Follicular Mantle Cell Burkitt Primary CNS Malt Splenic Marginal Zone Small Lymphocytic T-cell Other: specify

3 Complete for all patients 1. Scheduled to receive chemotherapy with an Anthracycline ( Doxorubicin or Epirubicin)? If yes, what dose? Doxorubicin < 240mg/m2 Doxorubicin > 240mg/m2 Epirubicin < 400 mg/2 Epirubicin > 400 mg/m2 2. Has received or is currently receiving chemotherapy? 3. Has received an anthracycline within the last 6 months? 4. Current use of statin therapy? 5. Atherosclerotic cardiovascular disease (ASCVD) defined by history of acute coronary syndromes, MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin. 6. Significant ventricular arrhythmias (>20 PVCs/min due to gating difficulty) atrial fibrillation with uncontrolled ventricular response to 75 years of age with diabetes? 8. Prior LVEF? If yes, Date obtained (most recent) / / Result: Obtained by: Muga Echo MRI 9. Uncontrolled hypothyroidism? 10. Current or history of hepatic dysfunction? 11. Recent history of substance abuse or another medical condition that might compromise safety or the successful completion of the study. 12. Does patient have any of the following: ferromagnetic cerebral aneurysm clips intraorbital/intracranial metal, pacemaker, defibrillator, functioning neurostimulator devices or other implanted electronic devices 13. Symptomatic Claustrophobia? 14. Able to hold breathe for 10 seconds? 15. Allergy to contrast dye? (If yes, notify MRI staff) 16. History of allergic reactions attributed to compounds of similar chemical or biologic composition to Atorvastatin? 17. Is patient able to provide informed consent? 18. Is patient diabetic between the ages of years old? 19. ECOG performance status? 0 / Current use of the following CYP 3A4 inhibitors: Boceprevir, Clarithromycin, Cyclosporine (oral), Darunavir plus ritonavir, Fosamprenavir, Fosamprenavir plus ritonavir, Gemfibrozil, Grapefruit juice >1 liter per day, Itraconazole, Lopinavir plus ritonavir, Nelfinavir, Saquinavir plus ritonavir, Telaprevir, Tipranavir plus ritonavir

4 21. Current use of the following medications: Rifampin Digoxin 22. Following Lab parameters performed within 30 days prior to registration: (Additional labs are required at baseline but are not needed to meet registration requirements.) LDL < 190 mg/dl Alanine aminotransferase level (ALT) < 3 x ULN Aspartate aminotransferase level (AST) < 3 x ULN Total bilirubin < 2.0 TSH < 1.5 times ULN Creatine kinase < 2.5 x ULN Glucose < 126 (Diabetics years of age are not eligible, See 4.2.2) Were labs drawn fasting or non-fasting? 23. Is patient pregnant or breast-feeding? 24. Negative serum pregnancy test within 10 days prior to registration for women of child-bearing potential? If Yes, date of test / / N/A 25. Name of site personnel certified to perform cognitive testing? 26. Other primary cancer diagnosis? If yes, select type: Lung Colorectal CNS Endocrine/Neuroendocrine Head & Neck Melanoma Gyn Sarcoma/GIST Myeloma Leukemia Lymphoma Genitourinary/Germ Cell/Renal Myelodysplastic Unknown Primary Other breast primary Other (Specify) 27. Received prior radiation to chest? If Yes, Right side Left side Bilateral Total Dose cgy Total Dose per fraction cgy # Fractions Complete section below only if patient has received prior chemotherapy, targeted therapy or radiation? If Yes, provide any of the following information known. If No, skip to next page.

5 28. If yes, year of the last chemotherapy treatment. (yyyy) 29. Check all that apply and provide dose per m/2 and # cycles received: If dosage decreased during treatment enter starting dose. If AUC is used to calculate dose, enter AUC and number. Example: AUC 6 Dose m/2 # of Cycles Bevacizumab (Avastin) Bendamustine (Treanda) Bexarotene (Targretin) Bleomycin (Blenoxane) Bortezomib (Velcade) Carboplatin (Carbo) (Paraplatin) Carmustine (Bicnu) Cisplatin (Platinol) Cytarabine (Cytosar) (DepoCyt) Cyclophosphamide (Cytoxan) Dacarbazine (DTIC) Doxorubicin (Adriamycin) Docetaxel (Taxotere) Epirubicin (Ellence) Etoposide (Vepesid) (VP-16) (Etopophos) Fludarabine (Fludara) Fluorouracil (5-FU) (Adrucil) Gemcitabine (Gemzar) Ibritumomab tiuxetan (Zevalin) Ifosfamide (Ifex) Lapatinib (Tykerb) Mechlorethamine (Mustargen) (Ni M d) Melphalan (Alkeran) Methotrexate (MTX) Mitoxantrone (Novantrone) Ontak (Denileukin Diftitox) Oxaliplatin (Eloxatin) Paciltaxel (Taxol) CDDP (Cisplatin) Pentostatin (Nipent) Rituximab (Rituxan) Tositumomab (Bexxar) trastuzumab (Herceptin) Vinblastine (Velban) Vincristine (Oncovin) Vinorelbine (Navelbine) Vorinostat (Zolinza) Xeloda (Capecitabine) Other, specify

6 This page may be detached and given to participant to complete. Information on this page will be needed at registration. Please place a check by the correct in each column. 1. What is your marital status? Single, never married Married Living in a married like relationship Separated or Divorced Widowed 2. What is the highest grade you finished in school? Did not go to school 1-8 grades 9-11 grades High school graduate or GED Vocational or training school after HS Some college or Associate s degree College degree (Bachelor of Arts/ Bachelor of Science) Some post college work 3. What is your income range? under $10,000 $10,000 to $19,999 $20,000 to 34,999 $35,000 to $49,999 $50,000 to $74,999 $75,000 to $99,999 $100,000 to $149,999 $150,000 or more 4. What is your current job status? Not working Retired Homemaker, Raising children, care of others Employed (FT or PT) Disabled, unable to work Other (Specify) 5. Which of these statements best describe your main / primary job? Homemaker/ housewife Managerial/ Professional/ Specialty Technical/Sales/ Administrative support Service Operators, fabricators, and Laborers Other (Specify) Master s Degree Doctoral Degree (PHD, MD, JD) 6. What is your ethnicity Hispanic or Latino Not Hispanic or Latino 7. What is your race? White or Caucasian Black or African American American Indian or Alaskan Native Asian Native Hawaiian or Other Pacific Islander

7 Online Registration Log on to the WF NCORP Research Base registration web site at Enter your user name and password (which may be obtained by contacting June Fletcher-Steede at In the Patient Registration and Protocol Information table, click the Register Patient/Patient Info, with the corresponding protocol number found in the drop down box to the right. Fill in the eligibility criteria forms using the drop down boxes. If further information is needed by Biologics or Data Management, they will contact you. Once the patient information has been entered online print a copy of the eligibility checklist/registration form for your records. Press the submit button, a confirmation page will appear. Print this confirmation sheet for your records. The WF NCORP On-line Protocol Registration/Eligibility form, initial flow sheet, signed consent, histology reports, scan reports and lab reports should be faxed to (336) or mailed to Data Management: Research Base Data Management Center 2000 West 1 st Street, Piedmont Plaza II, Suite 101 Winston-Salem, NC These forms should be retained in the patient s study file. These forms will be evaluated during an institutional WF NCORP Research Base site member audit. If you have questions related to the registration process or require assistance with registration, please contact the WF NCORP Research Base DMC between 8:30am and 4:00pm EST, Monday through Friday at (336) or

8 Registration 1. MD Group: (select from drop-down box) 2. IRB Code: (select from drop-down box) 3. New Patient ID: (Assigned at Registration) 4. Registration 5. Consent 6. Secondary Institution: (select from drop-down box) 7. MD Number: (select from drop-down box) 8. ICD-9 Code: (select from drop-down box) 9. DOB (MM/DD/YYYY): 10. Height (in): 11. Weight (lbs): 12. Zip Code: 13. County of Residence: 14. Gender: Male Female 15. Race: (Check all that apply) White Black or African American Unknown Asian American Indian or Alaskan Native Multi-Racial Native Hawaiian or other Pacific Islander 16. Ethnicity: Non Hispanic or Latino Hispanic or Latino Unknown 17. Insurance (list all that apply) Medicare Medicaid Private None 18. Any part of care at VA? Yes No 19. Site Contact person: 20. Site contact phone Number (xxx-xxx-xxxx): 21. Site contact Comments:

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data Key Fields Sequence Number Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous

More information

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies: VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Incidence: The incidence of acute and delayed N&V was investigated in highly and moderately emetogenic

More information

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data

Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Hodgkin and Non-Hodgkin Lymphoma (LYM) Post-Infusion Data Registry Use Only Sequence Number: Date Received: CIBMTR Center Number: CIBMTR Research ID: Event date: / / Visit 100 day 6 months 1 year 2 years

More information

To help doctors give their patients the best possible care, the American

To help doctors give their patients the best possible care, the American Patient Information Resources from ASCO What to Know ASCO s Guideline on Preventing Vomiting Caused by Cancer Treatment SEPTEMBER 2011 KEY MESSAGES The risk of nausea and vomiting depends on the specific

More information

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC Medication Review Cancer Chemotherapy Drugs Pharmacy Technician Training Systems Passassured, LLC Medication Review, Cancer Chemotherapy Drugs PassAssured's Pharmacy Technician Training Program Medication

More information

Acute Lymphocytic Leukemia

Acute Lymphocytic Leukemia Acute Lymphocytic Leukemia Splenectomy (Removal of Spleen) 6-Mercaptopurine (Purinethol, 6-MP) Alemtuzumab (Campath ) Arsenic Trioxide (Trisenox ) Bendamustine (Treanda ) Bexarotene (Targretin ) Bleomycin

More information

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1

HCPCS Code/ generic (Brand) Name J7506. J8520 capecitabine (Xeloda) 1. J8521 capecitabine. J8530 cyclophosphamide. (Cytoxan) 1 drug and administration compendia Current Price () J7506 Prednisone, oral, per 5 mg 12/1/07 $0.07 $0.19 N/A prednisone 2 J8520 capecitabine (Xeloda) 1 Capecitabine, oral, 150 mg 8/1/07 $5.79 $4.59 N/A

More information

Bladder Cancer Pathways (Urothelial)

Bladder Cancer Pathways (Urothelial) Bladder Cancer Pathways (Urothelial) Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op

More information

Introduction to Antineoplastic Prescribing

Introduction to Antineoplastic Prescribing Introduction to Antineoplastic Prescribing Robert Bradbury, R.Ph., BCPS Clinical Coordinator H. Lee Moffitt Cancer Center Objectives Meet the following goals concerning antineoplastic prescribing: Understand

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lynparza) Reference Number: CP.PHAR.360 Effective Date: 10.03.17 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Chemotherapy 101 for Radiation Oncology Workers

Chemotherapy 101 for Radiation Oncology Workers Chemotherapy 101 for Radiation Oncology Workers James Sinclair, M.D. CCARE/Medical Director Scripps Cancer Center March 9, 2013 Category 1) Alkylating agents Alkylating agents directly damage DNA to prevent

More information

Bladder Cancer (Urothelial) Pathways

Bladder Cancer (Urothelial) Pathways Bladder Cancer (Urothelial) Pathways Patient Name: Date of Birth: Member Number: Treatment Start Date: ICD-10 Code: Pathology: Stage: 0a 0is I II III IV Recurrent Line of Treatment: Neoadjuvant/Pre-Op

More information

My Personalized Breast Cancer Worksheet

My Personalized Breast Cancer Worksheet My Personalized Breast Cancer Worksheet KNOW For Early-Stage Breast Cancer. No Questions. Only Results. No two tumors are alike. What are the characteristics of your breast cancer and how will that effect

More information

Ovarian Cancer. compendia TREATMENT OF

Ovarian Cancer. compendia TREATMENT OF drug & compendia TREATMENT OF Ovarian Cancer With each publication, ManagedCare Oncology s drug & Compendia highlights a single medication or a group of medications that could be utilized in the management

More information

Name: Date of Birth: Address: City: State: Zip Code: Phone Number: Cell Phone: Work Number: Race: Primary Language: Secondary Language:

Name: Date of Birth: Address: City: State: Zip Code: Phone Number: Cell Phone: Work Number:   Race: Primary Language: Secondary Language: Address: Phone Number: Cell Phone: Work Number: Email: Last 4 of SS #: Patient Demographic Information: Gender: Male Female Marital Status Single Married Widowed Divorced Other: Ethnicity Hispanic or Latino

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

COME HOME Innovative Oncology Business Solutions, Inc.

COME HOME Innovative Oncology Business Solutions, Inc. Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment

More information

BAYLOR SCOTT & WHITE HEALTH GENETICS QUESTIONNAIRE PATIENT INFORMATION

BAYLOR SCOTT & WHITE HEALTH GENETICS QUESTIONNAIRE PATIENT INFORMATION PATIENT INFORMATION Name: Address: (Last) (First) (Middle) (Street) (City) (State) (Zip) Home Phone: Cell Phone: Email Address: Birth Date: Age: When is the best time to contact you? May we email you for

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Verzenio) Reference Number: CP.PHAR.355 Effective Date: 10.24.17 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this

More information

Hereditary Cancer Risk Program

Hereditary Cancer Risk Program Hereditary Cancer Risk Program Family History and Risk Assessment Questionnaire Please answer questions to the best of your ability in order to help us establish your risk assessment. Write in unk (unknown)

More information

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #:

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #: Patient Registration Please Print Clearly Date: Last Name: First Name: Middle Initial: Sex: Date of Birth: / / Age: Social Security: - - Address: City: State: Zip Code - Circle Preferred Phone Number Home

More information

Cancer Genetics Baylor All Saints Medical Center at Fort Worth

Cancer Genetics Baylor All Saints Medical Center at Fort Worth Cancer Genetics Baylor All Saints Medical Center at Fort Worth Thank you for your interest in the Hereditary Cancer Risk Program (HCRP). Please complete the family history and risk factor questionnaire

More information

PATIENT INFORMATION. (Last) (First) (Middle) (Last) (City) (State) (Zip)

PATIENT INFORMATION. (Last) (First) (Middle) (Last) (City) (State) (Zip) PATIENT INFMATION : Address: (Last) (First) (Middle) (Last) (City) (State) (Zip) Home Phone: Cell Phone: Email address: Birth date: : Gender: When is the best time to contact you? May we email you for

More information

Exhibit B United States Patent Application 20020012663 Kind Code A1 Waksal, Harlan W. January 31, 2002 Treatment of refractory human tumors with epidermal growth factor receptor antagonists Abstract A

More information

Personal Information. Full Name: Address: Primary Phone: Yes No Provider Yes No. Alternate Phone: Yes No Provider Yes No

Personal Information. Full Name: Address: Primary Phone: Yes No Provider Yes No. Alternate Phone: Yes No Provider Yes No OFFICE USE ONLY: Date of Intake: ID#: Staff mbr: Personal Information Full Name: Address: _ Last First M.I. Street Address Apartment/Unit # City State Zip Code County Date of Birth: Age: Mobile phone?

More information

Adjuvant Systemic Therapy in Early Stage Breast Cancer

Adjuvant Systemic Therapy in Early Stage Breast Cancer Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington

More information

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

TRANSPARENCY COMMITTEE OPINION. 29 April 2009

TRANSPARENCY COMMITTEE OPINION. 29 April 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)

More information

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Supportive Care in Cancer Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A Systematic Review of the Medicare Database Romina Sosa, Shuling Li, Julia T. Molony, Jiannong

More information

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time.

Figure 1: PALLAS Study Schema. Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Figure 1: PALLAS Study Schema Endocrine adjuvant therapy may have started before randomization and be ongoing at that time. Approximately 4600 patients from approximately 500 global sites will be randomized

More information

BLOOD AND LYMPH CANCERS

BLOOD AND LYMPH CANCERS BLOOD AND LYMPH CANCERS 2 Blood and Lymph Cancers Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology Edited by Kenneth C. Anderson, MD Harvard Medical School and Dana-Farber

More information

Patient Information. Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone: address:

Patient Information. Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone:  address: Patient Information Name: (Last) (First) (Middle) Address: (Street) (City) (State) (Zip) Home Phone: Cell Phone: Email address: Birth date: _ Age: Social Security.: When is the best time to contact you?

More information

TRANSPARENCY COMMITTEE OPINION. 15 February 2006

TRANSPARENCY COMMITTEE OPINION. 15 February 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial

More information

The Muscatine Study Heart Health Survey

The Muscatine Study Heart Health Survey The Muscatine Study Heart Health Survey PARTICIPANT ID LABEL (include study ID, name, DOB, gender) Today s Date: - - (MM-DD-YYYY) Thank you for agreeing to participate in the International Childhood Cardiovascular

More information

Haematology, Oncology and Palliative Care Directorate.

Haematology, Oncology and Palliative Care Directorate. Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile

More information

Philippine Society of Medical Oncology

Philippine Society of Medical Oncology Philippine Society of Medical Oncology Unit 1418, 14/F, orth Tower, Cathedral Heights Bldg., St. Luke s Medical Center E. Rodriguez Sr. Avenue, Quezon City 1099, Philippines Telefax: (632) 721-9326/ 723-0101

More information

CIT-06 Eligibility Questionnaire

CIT-06 Eligibility Questionnaire Today s Date: Last Name: First Name: Middle Name: Date of Birth: Height: Weight (lbs): PERSONAL CONTACT INFORMATION Street Address: City: State: Zip code: Home Phone: Cell Phone: Work Phone: Email Address:

More information

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #:

Pharmacy and Referrals Pharmacy Name, Street Address & Telephone #: Primary Care Physician s Name, Location & Telephone #: Patient Registration Please Print Clearly Date: Last Name: First Name: Middle Initial: Sex: Date of Birth: / / Age: Social Security: - - Address: City: State: Zip Code - Home Phone #: Work Phone #: Cell

More information

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy

Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic

More information

BRCA Precertification Information Request Form

BRCA Precertification Information Request Form BRCA Precertification Information Request Form Failure to complete this form in its entirety may result in the delay of review. Fax to: BRCA Precertification Department Fax number: 1-860-975-9126 Section

More information

o Kidney Cancer o Liver Cancer o Tremor o Tuberculosis o B12 Deficiency o Esophageal Cancer o Liver Disease o Pituitary Tumor o Uterine o Neurological

o Kidney Cancer o Liver Cancer o Tremor o Tuberculosis o B12 Deficiency o Esophageal Cancer o Liver Disease o Pituitary Tumor o Uterine o Neurological Adult New Patient Registration PATIENT DOB: / / MONTH DAY YEAR PATIENT NAME: LAST FIRST MI o Abnormal Heartbeat Patient Medical History: Please mark all that apply o Chronic Headaches o Hepatitis C o Neuropathy

More information

Subject ID: I N D # # U A * Consent Date: Day Month Year

Subject ID: I N D # # U A * Consent Date: Day Month Year IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be

More information

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced Class Medicine Name Nappi Strength Form Size Route Abiraterone Acetate ZYTIGA

More information

Appendix ZOOM Etude pour site internet

Appendix ZOOM Etude pour site internet Appendix ZOOM Etude pour site internet Indication Traitement adjuvant pour des patients présentant une mutation germinale des gènes BRCA1/2 et un risque élevé de cancer du sein primaire HER2 négatif Title

More information

Notto Chiropractic Health Center Patient Information

Notto Chiropractic Health Center Patient Information Notto Chiropractic Health Center Patient Information Acct #: Name: Preferred Name: Address: City: State: Zip: Home Phone: ( ) - _. Work Phone: ( ) -. Who Referred You? In Case of Emergency: Phone Number:

More information

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment? Breast Cancer Breast Cancer Excess Estrogen Exposure Nulliparity or late pregnancy + Early menarche + Late menopause + Cystic ovarian disease + External estrogens exposure + Breast Cancer Excess Estrogen

More information

Guidelines for the Use of Anti-Emetics with Chemotherapy

Guidelines for the Use of Anti-Emetics with Chemotherapy Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting

More information

Patient Information Form

Patient Information Form Patient Information Form Welcome to West Cancer Center We want to provide excellent service. The following information will allow us to accurately handle your billing and insurance. First Date Referring

More information

MASCC Guidelines for Antiemetic control: An update

MASCC Guidelines for Antiemetic control: An update MASCC / ISOO 17 th International Symposium Supportive Care in Cancer June 30 July 2, 2005 / Geneva, Switzerland MASCC Guidelines for Antiemetic control: An update Sussanne Börjeson, RN, PhD Linköping University,

More information

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)? 09/07/2016 Prior Authorization AETA BETTER HEALTH OF KETUCK (MEDICAID) PCSK9 Inhibitors (K88) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information

Patient Last Name First Name Middle Name. Home Address City State Zip. Date of Birth Age Social Security # - - Cell Phone Home Phone Work Phone

Patient Last Name First Name Middle Name. Home Address City State Zip. Date of Birth Age Social Security # - - Cell Phone Home Phone Work Phone Date Patient Last Name First Name Middle Name Gender (circle): Male Female Other: Marital Status (circle): Single Married Divorced Widowed Separated Home Address City State Zip Date of Birth Age Social

More information

NAME DATE Page 1. Other. Kidney Removed (Right, Left) Bladder Removed. Ovaries Removed for Endometriosis Breast Biopsy

NAME DATE Page 1. Other. Kidney Removed (Right, Left) Bladder Removed. Ovaries Removed for Endometriosis Breast Biopsy NAME DATE Page 1 Past Medical History: (please circle ALL that apply) Anxiety Hepatitis Arthritis Hypertension Artificial joints HIV/AIDS Asthma Hypercholesterolemia Atrial fibrillation Hyperthyroidism

More information

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients Guidelines on Chemotherapy-induced Nausea Vomiting in Pediatric Cancer Patients COG Supportive Care Endorsed Guidelines Click here to see all the COG Supportive Care Endorsed Guidelines. DISCLAIMER For

More information

Standard Breast Cancer Therapy

Standard Breast Cancer Therapy Pt s Who Don t Follow Treatment Standard Breast Cancer Therapy Deborah Thames R.T. (R)(M)(QM) Advancements in Breast Cancer Advancements in Breast Cancer Chemotherapy Full potential was recognized in the

More information

Long-Term and Late Effects of Treatment in Adults Facts

Long-Term and Late Effects of Treatment in Adults Facts Long-Term and Late Effects of Treatment in Adults Facts No. 22 in a series providing the latest information for patients, caregivers and healthcare professionals www.lls.org Information Specialist: 800.955.4572

More information

THE EMERGE SURVEY ON TAKING PART IN BIOBANK RESEARCH: VERSION A

THE EMERGE SURVEY ON TAKING PART IN BIOBANK RESEARCH: VERSION A THE EMERGE SURVEY ON TAKING PART IN BIOBANK RESEARCH: VERSION A What is this survey about? This survey is about your views on taking part in medical research. We want to understand what you think about

More information

Patient Interview Form

Patient Interview Form Patient Interview Form Patient Information First Name: Date Of Birth: Last Name: Email Please check one as your preferred email for communications Personal: Work: Race Select one or more White Unknown

More information

Clinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Zydelig) Reference Number: CP.CPA.278 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17

Clinical Policy: Lapatinib (Tykerb) Reference Number: CP.PHAR.79 Effective Date: Last Review Date: 11.17 Clinical Policy: (Tykerb) Reference Number: CP.PHAR.79 Effective Date: 10.01.11 Last Review Date: 11.17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important

More information

Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities )

Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities ) Management of Cardiotoxicity due to Systemic Cancer Therapy Left Ventricular Dysfunction Type 1 cardiac dysfunction Type 2 cardiac dysfunction Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension

More information

4/13/2010. Silverman, Buchanan Breast, 2003

4/13/2010. Silverman, Buchanan Breast, 2003 Tailoring Breast Cancer Treatment: Has Personalized Medicine Arrived? Judith Luce, M.D. San Francisco General Hospital Avon Comprehensive Breast Care Center Outline First, treatment of DCIS Sorting risk

More information

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting Definitions Acute nausea and vomiting Delayed nausea and vomiting Anticipatory nausea and vomiting Initial

More information

Triple Negative Breast Cancer: Part 2 A Medical Update

Triple Negative Breast Cancer: Part 2 A Medical Update Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is

More information

PERSONAL HISTORY NAME TODAY S DATE LAST FIRST MI LIST ANY ADDITIONAL NAMES USED: ADDRESS PHONE (STREET) (CITY) (STATE) (COUNTY) (ZIP)

PERSONAL HISTORY NAME TODAY S DATE LAST FIRST MI LIST ANY ADDITIONAL NAMES USED: ADDRESS PHONE (STREET) (CITY) (STATE) (COUNTY) (ZIP) PERSONAL HISTORY PERSONAL INFORMATION: NAME TODAY S DATE LAST FIRST MI LIST ANY ADDITIONAL NAMES USED: ADDRESS_ PHONE (STREET) (CITY) (STATE) (COUNTY) (ZIP) AGE: DATE OF BIRTH: SOCIAL SECURITY #: RACE:

More information

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles

More information

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION

More information

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for high grade and Burkitt s lymphoma used in the

More information

Symptom Management. Fertility and You

Symptom Management. Fertility and You Symptom Management Fertility and You Table of Contents 3 Will cancer impact my ability to have children? 4 How do I talk to my children about preserving their fertility during cancer treatment? 5 What

More information

Date: PATIENT INFORMATION Name SS# LAST FIRST MIDDLE INITIAL. Date of Birth Gender Male Female Marital Status Single Married Divorced Widowed

Date: PATIENT INFORMATION Name SS# LAST FIRST MIDDLE INITIAL. Date of Birth Gender Male Female Marital Status Single Married Divorced Widowed Date: PATIENT INFORMATION Name SS# LAST FIRST MIDDLE INITIAL Date of Birth Gender Male Female Marital Status Single Married Divorced Widowed Address Alternate Address STREET CITY STATE ZIP STREET CITY

More information

Clinical Management Guideline for Breast Cancer

Clinical Management Guideline for Breast Cancer Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:

More information

PLACE LABEL HERE. ACRIN 6659 Registration/Eligibility Institution

PLACE LABEL HERE. ACRIN 6659 Registration/Eligibility Institution A0 ACRIN 6659 Registration/Eligibility No Case No Instructions: For potential study participants, Part 2 must be completed before Part 1 If any of the answers, for Part 2, vary from the prompts provided

More information

LUCAS CHIROPRACTIC 903 Howard St. Walla Walla WA PATIENT INTAKE - update

LUCAS CHIROPRACTIC 903 Howard St. Walla Walla WA PATIENT INTAKE - update LUCAS CHIROPRACTIC 903 Howard St. Walla Walla WA 99362 PATIENT INTAKE - update Name Today s Date / / Date of Birth / / Address City State Zip Please check box for preferred communication means E-Mail Home

More information

Genetic Risk Evaluation and Testing Program

Genetic Risk Evaluation and Testing Program INSTRUCTIONS: Please complete this form to the best of your ability PRIOR to your appointment. Please remember to list ALL relatives, both living and deceased, regardless of if they have had cancer or

More information

Medicare Shared Savings Program Accountable Care Organization (ACO) Measure Deep Dive Series

Medicare Shared Savings Program Accountable Care Organization (ACO) Measure Deep Dive Series Medicare Shared Savings Program Accountable Care Organization (ACO) Measure Deep Dive Series Preventive Care and Screening (Prev-13) Measure 42 Statin Therapy for the Prevention and Treatment of Cardiovascular

More information

Breast Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology

Breast Cancer. Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology Breast Cancer Trusted Information to Help Manage Your Care from the American Society of Clinical Oncology ABOUT ASCO Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO ) is committed

More information

Home and Community Based Services (HCBS)

Home and Community Based Services (HCBS) To Whom It May Concern: To be considered for membership, the following must be submitted: 1. A Fountain House Membership Application and supplementary substance abuse questionnaire (included at the end

More information

Nutrition First Because it matters.

Nutrition First Because it matters. LuAnne Petrie Nutrition Consultant MS, RD, CDE Nutrition First Because it matters. 415 State Route 34 Colts Neck NJ 07722 info@nutritionfirstllc.com www.nutritionfirstllc.com (908) 692-4140 BACKGROUND

More information

Registration Form Women s Health Initiative

Registration Form Women s Health Initiative YWCA WHI 1500 14 th St. Lubbock, Texas 79401 Phone: (806) 687-8858 Fax: (806) 784-0698 1 Registration Form Women s Health Initiative Date: Name (Last, First, middle, Maiden) Age: Date of Birth SS # Mailing

More information

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia Tunisian Health System: Social Welfare with a Public insurance for all citizens including Indigent persons. (± Additional private insurance) Choice: Public Hospital/Private Clinics (Indigents Public H)

More information

2016 Pharmacist Re-Licensure Survey Instrument

2016 Pharmacist Re-Licensure Survey Instrument 1. Sex a. Male b. Female 2016 Pharmacist Re-Licensure Survey Instrument 2. Ethnicity: Are you Hispanic or Latino? a. Yes b. No 3. Race (Check all that apply.) a. American Indian or Alaska Native b. Black

More information

Patient 1: Patient 2:

Patient 1: Patient 2: Appendix A Compiled by Dr. Raymond Ngeh and Dr. Robert Luk Clinical notes and PET/CT scan images of eleven patients: 1. Middle age woman has cancer of the pancreas in the body of the gland. After just

More information

KAREN J. SUNDBY, M.D. PLEASE COMPLETE THE FOLLOWING MEDICAL HISTORY FORM

KAREN J. SUNDBY, M.D. PLEASE COMPLETE THE FOLLOWING MEDICAL HISTORY FORM KAREN J. SUNDBY, M.D. PLEASE COMPLETE THE FOLLOWING MEDICAL HISTORY FORM Dr. Mr. Mrs. Ms. Miss New Patient or Returning Patient FULL LEGAL NAME: Reason for today s visit: Mohs Excision Skin Check other:

More information

YESCARTA (axicabtagene ciloleucel)

YESCARTA (axicabtagene ciloleucel) YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

Patient Profile. Full Name: Address: Work Phone: Date of Birth: Social Security #: (Circle One) Full Time / Part Time. Emergency Contact: Number:

Patient Profile. Full Name: Address: Work Phone: Date of Birth: Social Security #: (Circle One) Full Time / Part Time. Emergency Contact: Number: Patient Profile Full Name: Address: City: State: Zip Code: Home Phone: Cell Phone: Work Phone: Date of Birth: Social Security #: Email Address: Employer: (Circle One) Full Time / Part Time Emergency Contact:

More information

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University

More information

PATIENT INFORMATION. Name: First Name MI Last Name. Date of Birth: / / Sex: Male / Female / Declined SSN:

PATIENT INFORMATION. Name: First Name MI Last Name. Date of Birth: / / Sex: Male / Female / Declined SSN: PATIENT INFORMATION Name: First Name MI Last Name Date of Birth: / / Sex: Male / Female / Declined SSN: Race: Ethnicity: Hispanic/Latino Not Hispanic/Latino Declined Marital Status: Single Married Divorced/Separated

More information

Indium-111 Zevalin Imaging

Indium-111 Zevalin Imaging Indium-111 Zevalin Imaging Background: Most B lymphocytes (beyond the stem cell stage) contain a surface antigen called CD20. It is possible to kill these lymphocytes by injecting an antibody to CD20.

More information

Notification to Implement Issued by pcodr: December 14, 2012

Notification to Implement Issued by pcodr: December 14, 2012 PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further

More information

Gender: Male Female Age: Current Address: City: State: Zip Code: Work Phone: Is it okay to leave a message? VISIT INFORMATION

Gender: Male Female Age: Current Address: City: State: Zip Code: Work Phone: Is it okay to leave a message? VISIT INFORMATION SIENA PROACTIVE INTERNAL MEDICINE DR. DEBORAH BLENNER 45 Terry Road, Suite B Smithtown, NY 11787 www.sienaproactive.com Phone: (631) 656-8171 Fax: (631) 656-8173 PATIENT INFORMATION Last Name: First Name:

More information

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK

FREEDOM OF INFORMATION SOUTH EAST SCOTLAND CANCER NETWORK Dear Date 06/02/09 Your Ref Our Ref RM/1220 Enquiries to Richard Mutch Extension 89441 Direct Line 0131-536-9441 Direct Fax 0131-536-9009 Email richard.mutch@lhnhslothian.scot.nhs.uk FREEDOM OF INFORMATION

More information

Large Granular Lymphocyte (LGL) Leukemia Registry Page 1 of 6 PATIENT INFORMATION QUESTIONNAIRE

Large Granular Lymphocyte (LGL) Leukemia Registry Page 1 of 6 PATIENT INFORMATION QUESTIONNAIRE Patient Name: Patient / / Patient Information Large Granular Lymphocyte (LGL) Leukemia Registry Page 1 of 6 PATIENT INFORMATION QUESTIONNAIRE 1. On what date was this questionnaire completed? / / 2. Please

More information

Patient Information. First Name Middle Last Preferred Name. Street Address City State Postal Code

Patient Information. First Name Middle Last Preferred Name. Street Address City State Postal Code Ms. Patient Information First Name Middle Last Preferred Name Street Address City State Postal Code Work Phone ( ) Home Phone ( ) Cell Phone ( ) Email Preferred Contact Email Cell Home Work Emergency Contact

More information

Committee Approval Date: December 12, 2014 Next Review Date: July 2015

Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Medication Policy Manual Policy No: dru378 Topic: Akynzeo, netupitant/palonosetron Date of Origin: December 12, 2014 Committee Approval Date: December 12, 2014 Next Review Date: July 2015 Effective Date:

More information

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER European Medicines Agency Evaluation of Medicines for Human Use London, September 2006 Doc. Ref.: EMEA/384641/2006 ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER The Paediatric

More information

Patient Enrollment Sheet

Patient Enrollment Sheet Patient Enrollment Sheet PATIENT INFORMATION: LAST NAME FIRST NAME MIDDLE INIT. STREET CITY STATE ZIP SSN DOB / / MALE / FEMALE HOME PHONE CELL PHONE WORK PHONE E-MAIL ADDRESS EMPLOYER YOUR OCCUPATION

More information

Clinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date:

Clinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date: Clinical Policy: (Zydelig) Reference Number: ERX.SPA.269 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

CancerPACT Cancer Patients Alliance for Clinical Trials

CancerPACT Cancer Patients Alliance for Clinical Trials TM CancerPACT Cancer Patients Alliance for Clinical Trials Listing of Ongoing Cancer Clinical Trials in the Salinas Valley Winter 2008 I. Solid Tumors 1. Breast p.1 2. Central Nervous System p.2 3. Gastrointestinal

More information

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center

Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center Active Cancer Studies by Approval Date For additional information on any one of these studies contact the Lancaster General Cancer Center 717-544-3113 PROTOCOL NO STUDY TITLE PRINCIPAL INVESTIGATOR ECOG

More information

Please complete all pages of this form. Your physician will review the form with you during your appointment. Last Name: First Name: Middle Initial:

Please complete all pages of this form. Your physician will review the form with you during your appointment. Last Name: First Name: Middle Initial: Please complete all pages of this form. Your physician will review the form with you during your appointment. Patient Information Last Name: First Name: Middle Initial: Date of Birth: / / Age: SSN: - -

More information

Guideline Update on Antiemetics

Guideline Update on Antiemetics Guideline Update on Antiemetics Clinical Practice Guideline Special Announcements Please check www.asco.org/guidelines/antiemetics for current FDA alert(s) and safety announcement(s) on antiemetics 2 Introduction

More information